Emanuela Mazzon Selected Research

Interleukins

12/2019	In Silico and In Vivo Analysis of IL37 in Multiple Sclerosis Reveals Its Probable Homeostatic Role on the Clinical Activity, Disability, and Treatment with Fingolimod.
1/2016	Alternative source of stem cells derived from human periodontal ligament: a new treatment for experimental autoimmune encephalomyelitis.
6/2008	Glucocorticoid-induced tumor necrosis factor receptor-related (GITR)-Fc fusion protein inhibits GITR triggering and protects from the inflammatory response after spinal cord injury.
2/2008	Absence of endogenous interleukin-10 enhanced organ dysfunction and mortality associated to zymosan-induced multiple organ dysfunction syndrome.
1/2007	Genetic and pharmacological inhibition of GITR-GITRL interaction reduces chronic lung injury induced by bleomycin instillation.
3/2005	Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion.
10/2004	Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal antibody.
8/2002	Role of induced nitric oxide in the initiation of the inflammatory response after postischemic injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Emanuela Mazzon Research Topics

Disease

147	Inflammation (Inflammations) 06/2023 - 01/2002
56	Spinal Cord Injuries (Spinal Cord Injury) 12/2022 - 02/2005
32	Ischemia 12/2014 - 08/2002
31	Edema (Dropsy) 01/2019 - 05/2002
31	Necrosis 01/2016 - 01/2002
31	Shock 06/2012 - 03/2002
29	Myelitis 04/2012 - 02/2005
28	Lung Injury 03/2024 - 01/2002
28	Reperfusion Injury 01/2024 - 01/2002
28	Colitis 08/2011 - 05/2002
26	Multiple Sclerosis 02/2024 - 08/2013
26	Pleurisy (Pleuritis) 01/2024 - 01/2002
26	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2023 - 11/2014
25	Body Weight (Weight, Body) 05/2012 - 10/2002
22	Wounds and Injuries (Trauma) 09/2023 - 07/2002
19	Pancreatitis 03/2024 - 05/2002
19	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 08/2011 - 05/2002
18	Neoplasms (Cancer) 10/2021 - 06/2004
16	Multiple Organ Failure (MODS) 02/2024 - 10/2002
15	Alzheimer Disease (Alzheimer's Disease) 04/2023 - 12/2016
15	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2022 - 08/2013
15	Pneumonia (Pneumonitis) 10/2011 - 03/2004
14	Arthritis (Polyarthritis) 01/2024 - 10/2002
13	Parkinson Disease (Parkinson's Disease) 11/2023 - 01/2012
12	Neuroinflammatory Diseases 04/2023 - 01/2011
10	Periodontitis 08/2017 - 06/2005
10	Diarrhea 10/2015 - 05/2002
10	Experimental Arthritis 12/2011 - 01/2002
10	Septic Shock (Toxic Shock Syndrome) 07/2011 - 11/2002
9	Neuroblastoma 04/2023 - 07/2017
9	Hypoxia (Hypoxemia) 05/2020 - 12/2004
9	Hemorrhage 05/2012 - 05/2002
9	Weight Loss (Weight Reduction) 02/2009 - 07/2002
7	Disease Progression 11/2023 - 12/2016
7	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 06/2021 - 01/2015

Drug/Important Bio-Agent (IBA)

53	3-nitrotyrosineIBA 10/2015 - 05/2002
50	CytokinesIBA 10/2021 - 06/2002
41	Peroxidase (Myeloperoxidase)IBA 11/2011 - 02/2003
39	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2010 - 02/2003
34	CarrageenanIBA 01/2024 - 01/2002
25	NF-kappa B (NF-kB)IBA 12/2014 - 01/2002
24	Proteins (Proteins, Gene)FDA Link 11/2023 - 04/2006
24	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 12/2014 - 01/2002
23	EnzymesIBA 07/2020 - 01/2002
23	DinitrobenzenesIBA 08/2011 - 07/2002
22	LigandsIBA 01/2024 - 12/2003
22	ZymosanIBA 09/2011 - 01/2002
21	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 03/2024 - 01/2002
20	2,4-dinitrofluorobenzene sulfonic acidIBA 08/2011 - 07/2002
19	Sulfonic AcidsIBA 08/2011 - 05/2002
18	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2019 - 12/2004
18	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 12/2014 - 01/2002
17	CeruletideIBA 03/2024 - 05/2002
16	PPAR alphaIBA 01/2010 - 10/2004
15	AntioxidantsIBA 12/2022 - 07/2003
15	GlucocorticoidsIBA 02/2017 - 11/2004
14	Reactive Oxygen Species (Oxygen Radicals)IBA 06/2023 - 07/2002
14	Transcription Factors (Transcription Factor)IBA 10/2021 - 01/2002
14	Interleukin-1beta (Interleukin 1 beta)IBA 04/2009 - 01/2002
13	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2019 - 01/2002
13	Lipase (Acid Lipase)FDA Link 07/2012 - 05/2002
13	Amylases FDA Link 07/2012 - 05/2002
13	Peroxynitrous Acid (Peroxynitrite)IBA 11/2010 - 11/2002
13	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 05/2010 - 02/2005
12	moringinIBA 05/2021 - 01/2016
12	Neuroprotective AgentsIBA 01/2018 - 02/2011
11	CannabinoidsIBA 01/2024 - 11/2014
11	Collagen Type II (Type II Collagen)IBA 01/2024 - 10/2002
11	Poly Adenosine Diphosphate RiboseIBA 07/2011 - 08/2002
11	Bleomycin (Blenoxane)FDA LinkGeneric 07/2011 - 05/2005
10	MicroRNAs (MicroRNA)IBA 02/2024 - 08/2019
10	isothiocyanic acidIBA 03/2023 - 01/2015
10	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2002
10	thioglucosidaseIBA 04/2019 - 08/2013
10	P-SelectinIBA 10/2015 - 01/2002
9	MelatoninIBA 05/2020 - 04/2005
9	Interleukin-6 (Interleukin 6)IBA 01/2011 - 06/2002
8	Macrophage Migration-Inhibitory FactorsIBA 03/2020 - 01/2018
8	InterleukinsIBA 12/2019 - 08/2002
8	Dexamethasone (Maxidex)FDA LinkGeneric 09/2015 - 06/2005
8	AcidsIBA 04/2011 - 07/2002
8	ProstaglandinsIBA 07/2009 - 05/2002
7	Biomarkers (Surrogate Marker)IBA 02/2024 - 06/2005
7	Glycogen Synthase (Synthase I)IBA 01/2024 - 05/2006
7	LipopolysaccharidesIBA 03/2022 - 03/2003
7	GlucosinolatesIBA 01/2022 - 01/2016
7	CannabidiolIBA 06/2020 - 10/2015
7	PolyphenolsIBA 04/2016 - 05/2005
7	Fas Ligand Protein (Fas Ligand)IBA 11/2011 - 11/2006
7	Nitric Oxide Synthase (NO Synthase)IBA 11/2011 - 05/2002
7	Tyrosine (L-Tyrosine)FDA Link 05/2011 - 11/2005
7	Superoxides (Superoxide)IBA 11/2010 - 07/2002
7	Uridine Triphosphate (UTP)IBA 02/2010 - 02/2005
7	salicylhydroxamic acid (SHAM)IBA 01/2010 - 01/2004
7	Poly(ADP-ribose) Polymerase InhibitorsIBA 02/2007 - 01/2002
6	Monoclonal AntibodiesIBA 01/2024 - 10/2004

Therapy/Procedure

42	Therapeutics 01/2023 - 01/2002
34	Laminectomy 01/2015 - 02/2005
15	Intraperitoneal Injections 07/2012 - 05/2002
7	Ligation 05/2011 - 10/2005